 |
|
|
| |
PATIENT-REPORTED OUTCOMES THROUGH WEEK 48 OF ATLAS-2M: A STUDY OF LONG-ACTING CABOTEGRAVIR AND RILPIVIRINE ADMINISTERED EVERY FOUR OR EIGHT WEEKS
|
| |
| |
IAC 2020 July 6-10 Virtual
Reported by Jules Levin
V Chounta,1 ET Overton,2 A Mills,3 S Swindells,4 PD Benn,1 S Vanveggel,5 R van Solingen-Ristea,5 Y Wang,6 KJ Hudson,7 M Shaefer,7 DA Margolis,7 K Smith,7 W Spreen7
1ViiV Healthcare, Brentford, UK; 2University of Alabama at Birmingham, Birmingham, AL, USA; 3Men's Health Foundation, Los Angeles, CA, USA; 4University of Nebraska Medical Center, Omaha, NE, USA; 5Janssen Pharmaceutica NV, Beerse, Belgium; 6GlaxoSmithKline, Collegeville, PA, USA; 7ViiV Healthcare, Research Triangle Park, NC, USA
|
| |
|
|
|
|
|
